DAY 3 articles

EuroCTO: Rechanneling vs. Optimal Medical Treatment in Total Occlusions

EuroCTO: Rechanneling vs. Optimal Medical Treatment in Total Occlusions

Courtesy of the SBHCI. Chronic total occlusions represent around 18% of all coronary lesions. However, they account for just 5% of all interventions, which means that many patients only receive medical treatment. This prospective, open, multicenter study randomized patients with multivessel lesions in whom at least one of these was a chronic total occlusion. Patients

COMPARE-ACUTE: FFR para guiar la revascularización de vasos no culpables en la angioplastia primaria

COMPARE-ACUTE: FFR-Guided Non-Culprit Vessel Revascularization in Primary Angioplasty

Courtesy of the SBHCI. About 50% of patients admitted with acute ST-segment elevation myocardial infarction also present lesions in another vessel. Whether to treat these or not, and the optimal moment to treat non-culprit infarction-related vessels are still controversial issues.   The COMPARE-ACUTE study was recently published and showed that fractional flow reserve (FFR)-guided complete

AIDA: La trombosis de las plataformas bioabsorbibles sigue en la mira de los estudios

AIDA: bioresorbable scaffold thrombosis still a concern in studies

Courtesy of the SBHCI. This study presented at PCR and simultaneously published by NEJM still challenges the safety of bioresorbable scaffolds.   This was a multicenter noninferiority work carried out in the Netherlands, comparing 1:1 everolimus-eluting bioresorbable scaffold ABSORB and permanent-polymer everolimus-eluting stent Xience.   The primary endpoint was target-vessel failure (a composite of cardiac

DES_angioplastia_primaria

PRISON IV: DES with resorbable polymer vs. DES with permanent polymer in total occlusions

Courtesy of SBHCI. The PRISON IV trial compared the sirolimus eluting stent with ultra-thin struts and biodegradable polymer vs. the second-generation everolimus-eluting stent with thin struts and durable polymer in successfully recanalized chronic total occlusions. This is a sub-study with optical coherence tomography (OCT).   The study included 330 patients, 85% angiographically followed up at

SENTINEL Study: Cerebral Protection During TAVR

[SURTAVI] Sub-study of neurological events: more evidence in favor of TAVR

Courtesy of SBHCI. The occurrence of a periprocedural neurological events is associated to an increased risk of death and morbidity at long term, both for transcatheter aortic valve replacement (TAVR) and for surgery. The SURTAVI study, recently presented at the ACC meeting and simultaneously published by NEJM, showed that TAVR with self-expandable CoreValve or Evolut

Surgeon manipulating a flexible catheter

NOTION: TAVI with low risk at 4 year follow up

Courtesy of the SBHCI. There is little data about the use of transcatheter aortic valve replacement (TAVR) to treat patients with severe aortic stenosis at low surgical risk. Many of the questions involve long term duration of valves (over 10 years) when treating younger patients with longer life expectancy.   The NOTION study aims at comparing

Top